Based in the Bay Area, Attovia Therapeutics is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. Dr. Hubert Chen, accomplished drug developer…
Category: BIOPHARMACEUTICALS
Allakos, a clinical stage biotechnology company focused on developing novel therapeutics for allergy, inflammatory and proliferative diseases, named Dr. Lee as Chief Medical Officer. Dr. Lee has over 20 years of clinical research and development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused…
Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, named Pamela Wapnick, MBA, as Chief Financial Officer. Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles. Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech…
Ambrx Biopharma, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system, named Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive…
Chartwell Partners proudly announces its collaboration with Neurogene Inc., a pioneering clinical-stage company dedicated to delivering groundbreaking genetic therapies for individuals and families grappling with rare neurological conditions on the recruitment of Julie Jordan, M.D., as their esteemed Chief Medical Officer. With a wealth of experience spanning over two decades in both industry and clinical…
Based in Boston and South San Francisco, precision medicine focused Frontier Medicines, appointed Andy Krivoshik, MD, PhD, to serve as Chief Medical Officer. As Frontier begins its transition into a clinical stage entity focused on generating medicines against disease-causing proteins previously considered undruggable, Dr. Krivoshik will startup, build and lead the drug development team. He…
Chartwell Partners, a national leader in executive search and leadership advisory services, is thrilled to announce that Amy Bottoms has joined us as a Partner in our Biopharmaceuticals practice. With the recent appointments of Amy and Ellen Travers, Chartwell’s Biopharmaceuticals practice adds a wealth of industry specific executive search and inhouse talent acquisition experience across…
Chartwell is delighted to continue our partnership with neurology-focused Xenon Pharmaceuticals, assisting in the recruitment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary. Andrea brings considerable experience helping organizations transition from R&D to commercial stage, most notably during her twelve-year tenure with Biogen and the subsequent spinout of Bioverativ. She served as Executive…
Chartwell Partners is honored to have worked with Protagonist Therapeutics to recruit Arturo Molina, MD, MS, FACP, as Chief Medical Officer. Arturo will be instrumental in guiding the Company’s lead asset, rusfertide, through its global Phase 3 trials, potential regulatory submissions and commercialization. Rusfertide, a mimetic of the natural hormone hepcidin, could transform the treatment…
Chartwell Partners, a national leader in executive search services, announced today that Ellen Travers has joined the firm as a Partner, focused on Board and C-level assignments in our biopharmaceutical and consumer healthcare practices. In her most recent role as the leader of the Talent Acquisition team for Xontogeny, a life science accelerator, Ellen managed…